Back to top
more

Thermo Fisher Scientific (TMO)

(Real Time Quote from BATS)

$603.50 USD

603.50
63,559

-12.19 (-1.98%)

Updated Aug 5, 2024 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

    Here's Why Investors Should Buy Integra LifeSciences Now

    The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

      TransEnterix Senhance Surgical Robotic System Wins FDA Nod

      TransEnterix (TRXC) works on expanding in robotic surgery consistently.

        Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

        Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

          NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

          NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

            Abbott Banks on FDA Approvals and Buyouts, Competition Rife

            The market is upbeat about Abbott's (ABT) latest initiatives.

              Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

              The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.

                MedTech Players Eyeing Emerging Market Growth Opportunities

                The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.

                  LabCorp (LH) Strong on Strategic Planning, Competition Rife

                  LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

                    DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                    DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

                      Henry Schein Closes Merritt Buyout, Expands in Animal Health

                      Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

                        CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

                        CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

                          Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders

                          Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.

                            QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

                            The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

                              Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business

                              Express Scripts (ESRX) is consistently trying to expand its core PBM business.

                                Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

                                With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

                                  QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

                                  QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

                                    Illumina (ILMN) Strong on Product Launches, Competition Rife

                                    Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.

                                      Boston Scientific Grows on New Products, Currency Woe Ails

                                      Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.

                                        Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact

                                        Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.

                                          The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics

                                          The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, SeaSpine Holdings and EnteroMedics

                                            Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm

                                            Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.

                                              4 Momentum Stocks That May Survive the Health Policy Mess

                                              In view of the current political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable momentum picks.

                                                VWR's New Kitting Center in Czech Republic to Boost EMEA Arm

                                                VWR's new strategically located 35,000 square foot facility in Skalice, Czech Republic looks to drive the company's business growth in the high-prospect EMEA region.

                                                  Bio-Techne's New Simple Plex Cartridge Boosts Protein Segment

                                                  Bio-Techne (TECH) introduces a multi-analyte cartridge format for the Ella immunoassay platform. The cartridge provides more accurate results at a lower cost.